Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Orexin A
Overview
Orexin A is a 33-amino acid neuropeptide produced in the lateral hypothalamus that plays a critical role in the regulation of wakefulness, arousal, and energy homeostasis. It binds with high affinity to both orexin receptor 1 (OX1R) and orexin receptor 2 (OX2R), promoting cortical activation and stabilizing the wake state.
Mechanism of Action
Deficiency of orexin signaling is the hallmark of narcolepsy type 1, making orexin replacement a rational therapeutic strategy.
Research Summary & Key Findings
Preclinical studies in narcoleptic animal models have demonstrated that central administration of orexin A restores wakefulness and reduces cataplexy, with findings published in leading neuroscience journals in the early 2000s. Therapeutic development has been hindered by poor blood-brain barrier penetration and peptide instability, prompting focus on orexin receptor agonists rather than peptide replacement. No orexin A formulation has advanced to clinical trials in humans.
Clinical Status
Orexin A is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed: "Orexin A"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Orexin A"
Registered interventional and observational studies, including status and phase.
- PubChem: "Orexin A"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Cognitive
Semax
InvestigationalA synthetic heptapeptide analog of the ACTH(4-7) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) with nootropic and neuroprotecti...
View detailsSelank
InvestigationalA synthetic analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with an added Pro-Gly-Pro sequence for stabi...
View detailsCerebrolysin
InvestigationalA porcine brain-derived peptide preparation consisting of low-molecular-weight neuropeptides and free amino acids that m...
View detailsP21 (Peptide)
Research PhaseA small synthetic peptide derived from the active region of ciliary neurotrophic factor (CNTF) designed to promote neuro...
View detailsNo lawful pathway today
Orexin A is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.